Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway [Yahoo! Finance]
Kronos Bio, Inc. (KRON)
Company Research
Source: Yahoo! Finance
IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in 2025 Restructuring plan extends anticipated cash runway into the second half of 2026 Company to continue to focus discovery efforts on maturing projects and Genentech collaboration activities SAN MATEO, Calif., and CAMBRIDGE, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company's pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data. This plan positions the Company to maximize the potential of KB-0742, an inhibitor of CDK9, by exploring an extended dosing schedule while also continuing to progress KB-9558, a p300 KAT inhibitor, through ongoing IND
Show less
Read more
Impact Snapshot
Event Time:
KRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRON alerts
High impacting Kronos Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRON
News
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsGlobeNewswire
KRON
Earnings
- 3/21/24 - Beat
KRON
Sec Filings
- 3/21/24 - Form S-8
- 3/21/24 - Form 10-K
- 3/21/24 - Form 8-K
- KRON's page on the SEC website